Biochemistry, Genetics and Molecular Biology
BRCA1
100%
RAD51
100%
Dynamics
100%
Oncogene
85%
Cancer Cell
83%
DNA Damage
76%
BRCA2
61%
Quantitative Proteomics
50%
MUC1
50%
Sister Chromatid Exchange
50%
Cyclin E1
50%
Epidermal Growth Factor Receptor
50%
Messenger RNA
50%
Cyclin E
50%
Mediator
50%
Cisplatin
50%
DNA Repair
38%
Homologous Recombination
36%
DNA Replication
33%
Poly ADP Ribose Polymerase
31%
Erlotinib
25%
Genome Instability
20%
Sister Chromatid
16%
Oncogene C Myc
16%
Centromere
16%
Mitochondrial Membrane Transport Protein
16%
Translocase
16%
AAA+
16%
ATPase
16%
Genetics
16%
DNA Condensation
16%
Upregulation
16%
Cell Viability
16%
Cell Cycle Checkpoint
16%
Proteomics
14%
CDC25A
14%
Wild Type
10%
Tumor Volume
8%
STAT3
8%
Mouse
8%
Blood Sampling
8%
Mass Spectrometry
8%
Experimental Model
8%
Clinical Trial
8%
Differential Gene Expression
7%
Gene Expression Profiling
7%
Expression Analysis
7%
Gene Signature
7%
B Cell
7%
KRAS
7%
Medicine and Dentistry
Cisplatin
64%
Triple Negative Breast Cancer
64%
Ovarian Cancer
57%
Neoplasm
50%
Mediator
50%
Radioactive Tracer
50%
Checkpoint Kinase 2
50%
Somatostatin Receptor
50%
Oncogene
50%
Meningioma
50%
Cancer Cell
50%
Receptor Subtype
50%
DNA Damage Response
34%
Breast Cancer Cell Line
23%
Cell Cycle Checkpoint
23%
Ataxia Telangiectasia
21%
Malignant Neoplasm
19%
Binding Affinity
16%
The Cancer Genome Atlas
14%
Ovarian Cancer Cell Line
14%
Immunohistochemistry
12%
Cell Cycle
12%
Surgery
11%
Xenograft
11%
Tetraxetan
11%
Drug Delivery System
7%
Double Stranded DNA
7%
Disease
7%
Diffuse Large B-Cell Lymphoma
7%
Expression Analysis
7%
RNA Sequence
7%
Colorectal Carcinoma
7%
S Phase
7%
Transformed Cell Line
7%
Non-Transformed Cell
7%
Differential Gene Expression
7%
Gene Expression Profiling
7%
Therapeutic Window
7%
Breast Cancer
7%
Treatment Response
7%
Carboxylic Acid
5%
IC50
5%
Epileptic Absence
5%
Chemosensitivity
5%
Specific Tumor
5%
Recurrence Risk
5%
Combination Therapy
5%
DNA Repair
5%
Biodistribution
5%
Ex Vivo
5%
Keyphrases
EXO1
50%
DNA Lesions
50%
Breast Cancer Susceptibility Gene 1 (BRCA1)
50%
Octreotate
50%
FIGNL1
50%
High-grade Serous Ovarian Cancer (HGSOC)
50%
Platinum-based Treatment
50%
800CW-TATE
38%
Single-strand Annealing
22%
Tumor
16%
NAT10
16%
G3BP2
12%
BRCA2
11%
Vulnerability
11%
MOCS3
8%
DDX27
8%
SUM149
8%
Dynamic Biomarkers
8%
ERCC6
6%
Joint Compound
6%
DNA Translocase
6%
Chromosome Fragmentation
6%
Exchange number
6%
Inactivating mutation
5%
Sigma Phase
5%
Chromosomal Instability
5%
Homologous Recombination
5%
Re-resection
5%
Therapeutic Target
5%
BRCA1 Gene
5%
BRCA2 Gene
5%
DNA Double-strand Break Repair
5%
Binding Affinity Assays
5%
Meningioma Recurrence
5%
Meningioma Resection
5%
BRCA1, BRCA2
5%
Homologous Recombination Defect
5%
Poly(ADP-ribose)
5%
Genomic Instability
5%
Genomic Scars
5%
Stress Features
5%
Replication Stress Response
5%
P53 Inactivation
5%
Replication Speed
5%